Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
BEAM Logo

Beam Therapeutics Inc.

BEAM

Biological Products, (No Diagnostic Substances)

Mkt Cap

$2.203B

PE

-7.02

Debt

-

Cash

$177.7M

EV

-

FCF

-$391.9M

Market Cap

$2.203B

P/E Ratio

-7.02

Debt

-

Cash

$177.7M

EV

-

FCF

-$391.9M
Charts data: {"Earnings":[{"time":"2019-12-30","value":-91040000},{"time":"2020-12-30","value":-195869000},{"time":"2021-12-30","value":-370638000},{"time":"2022-12-30","value":-289088000}],"Sales":[{"time":"2019-12-30","value":18000},{"time":"2020-12-30","value":24000},{"time":"2021-12-30","value":51844000},{"time":"2022-12-30","value":60920000}],"Net Margins":[{"time":"2019-12-30","value":-5057.777777777777},{"time":"2020-12-30","value":-8161.208333333333},{"time":"2021-12-30","value":-7.149101149602654},{"time":"2022-12-30","value":-4.745370978332239}],"Assets":[{"time":"2019-12-30","value":156099000},{"time":"2020-12-30","value":451677000},{"time":"2021-12-30","value":1474453000},{"time":"2022-12-30","value":1341714000}],"Stockholders Equity":[{"time":"2019-12-30","value":-201104000},{"time":"2020-12-30","value":245561000},{"time":"2021-12-30","value":826738000},{"time":"2022-12-30","value":733474000}],"ROE":[{"time":"2019-12-30","value":0.4527010899832922},{"time":"2020-12-30","value":-0.7976388758801275},{"time":"2021-12-30","value":-0.44831373421809567},{"time":"2022-12-30","value":-0.39413530677297354}],"ROA":[{"time":"2019-12-30","value":-0.4814508741247542},{"time":"2020-12-30","value":-0.2939268548099638},{"time":"2021-12-30","value":-0.2513732211199679},{"time":"2022-12-30","value":-0.1939146494707516}]}

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector

  • ACLX Logo

    ACLX

  • ADMA Logo

    ADMA

  • ADPT Logo

    ADPT

  • ALEC Logo

    ALEC

  • ALLO Logo

    ALLO

  • AMGN Logo

    AMGN

  • AURA Logo

    AURA

  • AVXL Logo

    AVXL

  • BCRX Logo

    BCRX

  • BIIB Logo

    BIIB

  • CABA Logo

    CABA

  • CGEM Logo

    CGEM

  • CRBU Logo

    CRBU

  • CRSP Logo

    CRSP

  • DNLI Logo

    DNLI

  • EDIT Logo

    EDIT

  • EXEL Logo

    EXEL

  • FATE Logo

    FATE

  • FDMT Logo

    FDMT

  • GILD Logo

    GILD

  • HALO Logo

    HALO

  • HLVX Logo

    HLVX

  • HUMA Logo

    HUMA

  • ICVX Logo

    ICVX

  • IMVT Logo

    IMVT

  • INBX Logo

    INBX

  • IOVA Logo

    IOVA

  • ITOS Logo

    ITOS

  • KRYS Logo

    KRYS

  • KYMR Logo

    KYMR

  • MGTX Logo

    MGTX

  • MRNA Logo

    MRNA

  • NBIX Logo

    NBIX

  • NVAX Logo

    NVAX

  • PCVX Logo

    PCVX

  • PRME Logo

    PRME

In the chart Earnings are multiplied by this value.

Earnings Growth -
Earnings Stability -


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201912-202012-202112-2022TTM
Net Margin-510K%-820K%-710%-470%-380%
ROA-48%-29%-25%-19%-27%
ROE45%-80%-45%-39%-40%

What is the average Net Margin?

The average Net Margin over the past 5 years is -594.72%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +240.37%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -22.26%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +5.75%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -42.12%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +5.42%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201912-202012-202112-2022TTM
Debt FCF-----
Debt Equity-----
MIN
Graham Stability-----

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201912-2021Trend
Revenue1.4K%18%-7.9%
Net Income---
Stockholders Equity--11%-250%
FCF---

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -7.91%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -247.95%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.